Physician profile
Carl A Krantz
NPI 1548339021
$2,124.87
in general payments reported to CMS, 2019-2025
21 companies · $81.46 in 2025
The $81.46 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $100 · 2021: $399 · 2022: $515 · 2023: $582 · 2024: $125 · 2025: $81.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.99 |
| Education | $265.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $753.81 | 2019-2023 | Veozah, Myrbetriq |
| Abbvie INC. | $440.30 | 2019-2025 | |
| Aspira Women'S Health INC | $253.90 | 2022-2024 | Ova1 |
| Minerva Surgical, INC | $175.05 | 2020-2023 | |
| Pfizer INC. | $123.57 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $71.33 | 2023-2024 | Myfembree |
| Mayne Pharma Commercial LLC | $41.36 | 2021-2022 | |
| Therapeuticsmd, INC. | $39.92 | 2019-2022 | |
| Coopersurgical, INC. | $39.89 | 2022-2023 | Paragard T 380a |
| Myovant Sciences INC. | $21.39 | 2022 | |
| Hologic Sales and Service, LLC | $20.20 | 2022 | |
| Agile Therapeutics, INC. | $19.65 | 2021 | |
| Merck Sharp & Dohme LLC | $18.68 | 2022 | |
| Exeltis, USA INC. | $18.50 | 2021 | |
| Shield Therapeutics INC | $17.86 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $17.11 | 2024 | |
| Amgen INC. | $15.46 | 2025 | Evenity, Prolia |
| Meditrina | $15.27 | 2025 | |
| Avion Pharmaceuticals | $10.95 | 2019 | |
| Organon LLC | $10.67 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Krantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.